• Zijian Zhou, Jiancheng Lv, Hao Yu, Jie Han, Xiao Yang, Dexiang Feng, Qikai Wu, Baorui Yuan, Qiang Lu, and Haiwei Yang.
• Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, PR China.
• Mol Cancer. 2020 Jun 8; 19 (1): 104.

AbstractSince the breakthrough discoveries of DNA and histone modifications, the field of RNA modifications has gained increasing interest in the scientific community. The discovery of N6-methyladenosine (m6A), a predominantly internal epigenetic modification in eukaryotes mRNA, heralded the creation of the field of epi-transcriptomics. This post-transcriptional RNA modification is dynamic and reversible, and is regulated by methylases, demethylases and proteins that preferentially recognize m6A modifications. Altered m6A levels affect RNA processing, degradation and translation, thereby disrupting gene expression and key cellular processes, ultimately resulting in tumor initiation and progression. Furthermore, inhibitors and regulators of m6A-related factors have been explored as therapeutic approaches for treating cancer. In the present review, the mechanisms of m6A RNA modification, the clinicopathological relevance of m6A alterations, the type and frequency of alterations and the multiple functions it regulates in different types of cancer are discussed.

19 keywords...

hide…